Jun Matsubayashi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jun Matsubayashi has a total of 212 co-authors. Here are the top co-authors by number of shared publications:
- Tetsuya Takakuwa
Human Health Science, Graduate School of Medicine Kyoto University Kyoto Japan
12 shared publications - Toru Kanahashi
Human Health Science, Graduate School of Medicine Kyoto University Kyoto Japan
11 shared publications Hirohiko Imai
Innovation Research Center for Quantum Medicine Gifu University School of Medicine Gifu Gifu Japan
9 shared publications- Shigehito Yamada
Kyoto University Graduate School of Medicine
9 shared publications - Daisuke Hasegawa
Department of Pediatrics St. Luke's International Hospital Tokyo Japan
4 shared publications - Daisuke Tomizawa
Division of Leukemia and Lymphoma, Children's Cancer Center National Center for Child Health and Development Tokyo Japan
4 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by Wolters Kluwer Health in JU Open Plus
- Vol. 4 (10)
Propensity Score–Matched Comparison of Laparoscopic Transvesical Ureteral Reimplantation and Intravesical Open Ureterocystoneostomy for Primary Vesicoureteral Reflux: A Multicenter Study in Japan
Purpose: The aim of this study was to assess the real-world perioperative safety and reoperation risk of laparoscopic transvesical ureteral reimplantation (TVUR), using intravesical open ureterocystoneostomy as a reference procedure, in patients with primary vesicoureteral reflux (VUR). Materials and Methods: We retrospectively reviewed patients with primary VUR who underwent laparoscopic TVUR or intravesical open ureterocystoneostomy in Japan (2012-2022). Laparoscopic TVUR was defined as a laparoscopic intravesical (vesicoscopic) transvesical approach; robot-assisted intravesical procedures were excluded. Propensity score matching was performed using age, sex, height, weight, bilaterality, duplex ureter, ureterocele, and maximum VUR grade. The primary outcome was reoperation. Secondary outcomes included operative time, catheter removal, hospital stay, and complications. Results: Among 1330 patients (laparoscopic TVUR: n = 514; intravesical open ureterocystoneostomy: n = 816), 868 were matched (434 per group). Laparoscopic TVUR required longer operative time (median [interquartile range]: 262 [220-321] vs 182 [151-229] min; P < .001) but was associated with earlier catheter removal (3 [2-5] vs 6 [3-7] days; P < .001) and shorter hospitalization (5 [3-7] vs 7 [5-9] days; P < .001). Intraoperative and postoperative complications were more frequent with laparoscopic TVUR (4.4% vs 0.5% and 12.4% vs 4.1%, respectively; P < .001). Urinary peritonitis occurred only after laparoscopic TVUR. Reoperation was more common in this group (2.8% vs 0.7%; hazard ratio: 3.74, 95% confidence interval: 1.05-13.24; P = .041). Conclusions: In this multicenter propensity score–matched cohort of patients with primary VUR, laparoscopic TVUR was associated with earlier catheter removal and shorter hospitalization but higher complication and reoperation rates than intravesical open ureterocystoneostomy, underscoring the importance of careful patient selection and meticulous technique.
- 1 October 2026
- Published by Wolters Kluwer Health in JU Open Plus
- Vol. 4 (10)
Open AccessPropensity Score–Matched Comparison of Laparoscopic Transvesical Ureteral Reimplantation and Intravesical Open Ureterocystoneostomy for Primary Vesicoureteral Reflux: A Multicenter Study in Japan
Purpose: The aim of this study was to assess the real-world perioperative safety and reoperation risk of laparoscopic transvesical ureteral reimplantation (TVUR), using intravesical open ureterocystoneostomy as a reference procedure, in patients with primary vesicoureteral reflux (VUR). Materials and Methods: We retrospectively reviewed patients with primary VUR who underwent laparoscopic TVUR or intravesical open ureterocystoneostomy in Japan (2012-2022). Laparoscopic TVUR was defined as a laparoscopic intravesical (vesicoscopic) transvesical approach; robot-assisted intravesical procedures were excluded. Propensity score matching was performed using age, sex, height, weight, bilaterality, duplex ureter, ureterocele, and maximum VUR grade. The primary outcome was reoperation. Secondary outcomes included operative time, catheter removal, hospital stay, and complications. Results: Among 1330 patients (laparoscopic TVUR: n = 514; intravesical open ureterocystoneostomy: n = 816), 868 were matched (434 per group). Laparoscopic TVUR required longer operative time (median [interquartile range]: 262 [220-321] vs 182 [151-229] min; P < .001) but was associated with earlier catheter removal (3 [2-5] vs 6 [3-7] days; P < .001) and shorter hospitalization (5 [3-7] vs 7 [5-9] days; P < .001). Intraoperative and postoperative complications were more frequent with laparoscopic TVUR (4.4% vs 0.5% and 12.4% vs 4.1%, respectively; P < .001). Urinary peritonitis occurred only after laparoscopic TVUR. Reoperation was more common in this group (2.8% vs 0.7%; hazard ratio: 3.74, 95% confidence interval: 1.05-13.24; P = .041). Conclusions: In this multicenter propensity score–matched cohort of patients with primary VUR, laparoscopic TVUR was associated with earlier catheter removal and shorter hospitalization but higher complication and reoperation rates than intravesical open ureterocystoneostomy, underscoring the importance of careful patient selection and meticulous technique.
- Open Access
Efficacy and safety of risk-stratified chemotherapy with azacitidine for children with myeloid leukaemia with Down syndrome: protocol for a multicentre phase II trial (JCCG AML-D24)
Introduction: The prognosis of myeloid leukaemia associated with Down syndrome (ML-DS) is excellent with reduced-intensity chemotherapy; however, that of refractory or relapsed ML-DS remains dismal. These contrasting outcomes highlight the importance of risk-stratified therapy, based on reliable prognostic factors, to prevent treatment-related mortality and relapse. In addition, novel therapeutic strategies capable of overcoming the poor prognosis of high-risk patients are eagerly anticipated. Based on the results of molecular analyses, in vitro functional assays and anecdotal case reports, azacitidine (AZA), a hypomethylating agent, is a promising candidate for novel therapeutic strategies for high-risk ML-DS. Methods and analysis: In this multicentre, single-arm phase II clinical trial, the Japan Children’s Cancer Group AML-D24, we will stratify patients with newly diagnosed ML-DS according to age at diagnosis, GATA1 mutation status and treatment response. Patients GATA1 mutation who achieve morphological complete remission and are negative for flow cytometric measurable residual disease at the end of induction will be classified as the low-risk (LR) group and receive less intensive chemotherapy. The other participants, stratified into the non-LR group, will be treated with AZA-combined chemotherapy. The objective of this trial is to evaluate the efficacy and safety of AZA-combined chemotherapy in children with non-LR ML-DS. The primary endpoint is the 3-year event-free survival in the non-LR group. The planned enrolment is 145 patients, including 47 non-LR patients. The study period consists of a 7-year accrual period (including an enrolment suspension period for interim analysis) followed by a 3-year follow-up period for a total duration of 10 years. Ethics and dissemination: This study was approved by the National Hospital Organization Review Board for Clinical Trials (Nagoya, Japan) on 12 May 2025 and was registered in the Japan Registry of Clinical Trials ( https://jrct.mhlw.go.jp/latest-detail/jRCTs041250031 ). Written informed consent will be obtained from all patients and/or their guardians. The results of this study will be disseminated through publication in peer-reviewed journals and presentation at national and international scientific conferences. Trial registration number: jRCTs041250031.
Open AccessEfficacy and safety of risk-stratified chemotherapy with azacitidine for children with myeloid leukaemia with Down syndrome: protocol for a multicentre phase II trial (JCCG AML-D24)
Introduction: The prognosis of myeloid leukaemia associated with Down syndrome (ML-DS) is excellent with reduced-intensity chemotherapy; however, that of refractory or relapsed ML-DS remains dismal. These contrasting outcomes highlight the importance of risk-stratified therapy, based on reliable prognostic factors, to prevent treatment-related mortality and relapse. In addition, novel therapeutic strategies capable of overcoming the poor prognosis of high-risk patients are eagerly anticipated. Based on the results of molecular analyses, in vitro functional assays and anecdotal case reports, azacitidine (AZA), a hypomethylating agent, is a promising candidate for novel therapeutic strategies for high-risk ML-DS. Methods and analysis: In this multicentre, single-arm phase II clinical trial, the Japan Children’s Cancer Group AML-D24, we will stratify patients with newly diagnosed ML-DS according to age at diagnosis, GATA1 mutation status and treatment response. Patients GATA1 mutation who achieve morphological complete remission and are negative for flow cytometric measurable residual disease at the end of induction will be classified as the low-risk (LR) group and receive less intensive chemotherapy. The other participants, stratified into the non-LR group, will be treated with AZA-combined chemotherapy. The objective of this trial is to evaluate the efficacy and safety of AZA-combined chemotherapy in children with non-LR ML-DS. The primary endpoint is the 3-year event-free survival in the non-LR group. The planned enrolment is 145 patients, including 47 non-LR patients. The study period consists of a 7-year accrual period (including an enrolment suspension period for interim analysis) followed by a 3-year follow-up period for a total duration of 10 years. Ethics and dissemination: This study was approved by the National Hospital Organization Review Board for Clinical Trials (Nagoya, Japan) on 12 May 2025 and was registered in the Japan Registry of Clinical Trials ( https://jrct.mhlw.go.jp/latest-detail/jRCTs041250031 ). Written informed consent will be obtained from all patients and/or their guardians. The results of this study will be disseminated through publication in peer-reviewed journals and presentation at national and international scientific conferences. Trial registration number: jRCTs041250031.
- Open Access
- 1 July 2026
- Published by BMJ in BMJ Open Gastroenterology
- Vol. 13 (1) , e002404
Usefulness of indigo carmine chromoendoscopy for detecting gastric cancer and gastric adenoma during upper gastrointestinal endoscopy (INDIGO study): protocol for a prospective multicentre observational study
Introduction: Early gastric cancer is characterised by subtle mucosal and colour changes that frequently lead to missed lesions during routine endoscopy, making detection difficult. Indigo carmine spraying is a classical chromoendoscopic method to enhance mucosal surface irregularities and has been believed to have the potential to facilitate the detection of early gastric neoplasia. This method is widely used in Japan; however, whether it improves gastric neoplasm detection remains unclear. In this prospective study, we aim to evaluate the usefulness of indigo carmine spraying for detecting gastric cancer and gastric adenoma during upper gastrointestinal endoscopy in patients at high risk of gastric cancer. Methods and analysis: This prospective multicentre observational study will include over 30 institutions. Patients undergoing upper gastrointestinal endoscopy for surveillance after endoscopic treatment or pretreatment screening will be enrolled. The age range has been set from 20 years to 95 years, and patients for whom a biopsy will not be feasible will be excluded. Gastric observation will consist of two steps: the first will use white light imaging, followed by a second-pass observation after spraying 20–40 mL of indigo carmine at a concentration of 0.1–0.4%. The primary endpoint will be the proportion of patients with gastric cancer or adenoma lesions detected during the second-pass observation among those who undergo successful indigo carmine examination. A one-sided binomial test (α=0.05) will be used to compare the detection rate with a predefined threshold of 1.0%. We aim to enrol a total of 1050 patients to achieve 80% power. Ethics and dissemination: This study was approved by the Institutional Review Board of Kanagawa Cancer Center (approval number: 2025-92). Written informed consent will be obtained at the time of registration. Following completion of this research, the findings will be promptly compiled and published in appropriate academic conferences and peer-reviewed international journals. Trial registration number: UMIN000059685.
- 1 July 2026
- Published by BMJ in BMJ Open Gastroenterology
- Vol. 13 (1) , e002404
Open AccessUsefulness of indigo carmine chromoendoscopy for detecting gastric cancer and gastric adenoma during upper gastrointestinal endoscopy (INDIGO study): protocol for a prospective multicentre observational study
Introduction: Early gastric cancer is characterised by subtle mucosal and colour changes that frequently lead to missed lesions during routine endoscopy, making detection difficult. Indigo carmine spraying is a classical chromoendoscopic method to enhance mucosal surface irregularities and has been believed to have the potential to facilitate the detection of early gastric neoplasia. This method is widely used in Japan; however, whether it improves gastric neoplasm detection remains unclear. In this prospective study, we aim to evaluate the usefulness of indigo carmine spraying for detecting gastric cancer and gastric adenoma during upper gastrointestinal endoscopy in patients at high risk of gastric cancer. Methods and analysis: This prospective multicentre observational study will include over 30 institutions. Patients undergoing upper gastrointestinal endoscopy for surveillance after endoscopic treatment or pretreatment screening will be enrolled. The age range has been set from 20 years to 95 years, and patients for whom a biopsy will not be feasible will be excluded. Gastric observation will consist of two steps: the first will use white light imaging, followed by a second-pass observation after spraying 20–40 mL of indigo carmine at a concentration of 0.1–0.4%. The primary endpoint will be the proportion of patients with gastric cancer or adenoma lesions detected during the second-pass observation among those who undergo successful indigo carmine examination. A one-sided binomial test (α=0.05) will be used to compare the detection rate with a predefined threshold of 1.0%. We aim to enrol a total of 1050 patients to achieve 80% power. Ethics and dissemination: This study was approved by the Institutional Review Board of Kanagawa Cancer Center (approval number: 2025-92). Written informed consent will be obtained at the time of registration. Following completion of this research, the findings will be promptly compiled and published in appropriate academic conferences and peer-reviewed international journals. Trial registration number: UMIN000059685.
- 14 June 2026
- Published by Wiley in Developmental Dynamics
Prenatal sexual dimorphism in human pelvic tilt at the onset of fetal ossification
Background: Sexual dimorphism in pelvic morphology has been confirmed at the onset of primary ossification. Since pelvic tilt influences spinal alignment and bipedal locomotion, determining the initial emergence of sex‐specific tilt differences is crucial. Herein, we measured pelvic tilt and lumbosacral inclination angles (LSIAs) using magnetic resonance imaging in 72 human fetuses (crown–rump length [CRL], 50–225 mm; 34 males [M] and 38 females [F]). Results: The cranial–caudal axis was defined from the first to third sacral vertebrae, and sex differences were assessed using multiple regression analysis including sex, CRL subgroup, and their interaction. Females exhibited greater posterior iliac tilt than males (anterior superior iliac spine–posterior superior iliac spine line: least‐squares mean; [F] −19.6° vs. [M] −17.0°; p = .038). The LSIA (L1/S5–sacral promontory) was larger in males ([F] 166.3° vs. [M] 170.2°; p = .033), indicating more dorsally positioned sacra in females. Principal component analysis identified two major components representing os coxae rotation and sacral inclination to the lumbar spine, indicating independent developmental patterns. Conclusions: The findings demonstrate that pelvic sexual dimorphism includes tilt orientation from the onset of ossification, reflecting sex‐specific developmental trajectories during the prenatal period.
- 14 June 2026
- Published by Wiley in Developmental Dynamics
Prenatal sexual dimorphism in human pelvic tilt at the onset of fetal ossification
Background: Sexual dimorphism in pelvic morphology has been confirmed at the onset of primary ossification. Since pelvic tilt influences spinal alignment and bipedal locomotion, determining the initial emergence of sex‐specific tilt differences is crucial. Herein, we measured pelvic tilt and lumbosacral inclination angles (LSIAs) using magnetic resonance imaging in 72 human fetuses (crown–rump length [CRL], 50–225 mm; 34 males [M] and 38 females [F]). Results: The cranial–caudal axis was defined from the first to third sacral vertebrae, and sex differences were assessed using multiple regression analysis including sex, CRL subgroup, and their interaction. Females exhibited greater posterior iliac tilt than males (anterior superior iliac spine–posterior superior iliac spine line: least‐squares mean; [F] −19.6° vs. [M] −17.0°; p = .038). The LSIA (L1/S5–sacral promontory) was larger in males ([F] 166.3° vs. [M] 170.2°; p = .033), indicating more dorsally positioned sacra in females. Principal component analysis identified two major components representing os coxae rotation and sacral inclination to the lumbar spine, indicating independent developmental patterns. Conclusions: The findings demonstrate that pelvic sexual dimorphism includes tilt orientation from the onset of ossification, reflecting sex‐specific developmental trajectories during the prenatal period.
- 25 May 2026
- Published by Wiley in Developmental Dynamics
Determinants of midgut loop formation: Influence of midgut length, diameter, and location
Background: The midgut forms tertiary loops in the extraembryonic coelom, where biomechanical factors are thought to influence this process. The number of loops may stabilize once the midgut returns to the abdominal cavity. We therefore examined how midgut length and diameter affect the number of tertiary loops before and after intestinal return. Results: Magnetic resonance images from 50 human embryo and fetus specimens and serial tissue sections from six fetuses were analyzed. The midgut was divided into four segments, and the length of each segment and the tube diameter at a representative central loop were measured and subjected to regression analysis. In the extraembryonic coelom, loop number increased linearly with midgut length, whereas diameter showed no independent association. In the abdominal cavity, greater length was associated with more loops, whereas greater diameter tended to be associated with fewer loops, particularly in Segment‐2 and Segment‐4. This pattern may be related to the apparent attenuation of further loop increase after return to the abdominal cavity during later fetal development. Conclusions: The effects of midgut length and diameter on tertiary loop formation differ between the extraembryonic coelom and the abdominal cavity, highlighting the importance of midgut position in loop formation.
- 25 May 2026
- Published by Wiley in Developmental Dynamics
Determinants of midgut loop formation: Influence of midgut length, diameter, and location
Background: The midgut forms tertiary loops in the extraembryonic coelom, where biomechanical factors are thought to influence this process. The number of loops may stabilize once the midgut returns to the abdominal cavity. We therefore examined how midgut length and diameter affect the number of tertiary loops before and after intestinal return. Results: Magnetic resonance images from 50 human embryo and fetus specimens and serial tissue sections from six fetuses were analyzed. The midgut was divided into four segments, and the length of each segment and the tube diameter at a representative central loop were measured and subjected to regression analysis. In the extraembryonic coelom, loop number increased linearly with midgut length, whereas diameter showed no independent association. In the abdominal cavity, greater length was associated with more loops, whereas greater diameter tended to be associated with fewer loops, particularly in Segment‐2 and Segment‐4. This pattern may be related to the apparent attenuation of further loop increase after return to the abdominal cavity during later fetal development. Conclusions: The effects of midgut length and diameter on tertiary loop formation differ between the extraembryonic coelom and the abdominal cavity, highlighting the importance of midgut position in loop formation.
- 25 March 2026
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 45 (10) , 872-878
Change in Seasonality of Kawasaki Disease After the COVID-19 Pandemic: A 10-year Survey in Shiga, Japan (2015–2024)
Background: During the coronavirus disease 2019 (COVID-19) pandemic, the seasonality of Kawasaki disease (KD) in Japan shifted from winter dominance to summer dominance. However, it remains unclear whether this pattern reverted after infection mitigation measures were lifted in 2023. Methods: We conducted a population-based retrospective survey among all hospitalized patients with KD in Shiga Prefecture, Japan, from 2015 to 2024. Monthly variations in the KD incidence from 2021 to 2024 were analyzed using the 2015–2019 period as reference. We also examined the seasonality of 10 common pediatric infectious diseases and seasonal influenza during the study period. Results: A total of 2077 patients with KD were identified. The KD incidence remained low during the implementation of public health measures against COVID-19 from 2020 to 2022. Subsequently, the incidence reached the maximum in 2023 (128.2 per 100,000 person-years), coinciding with the lifting of infection mitigation measures; the incidence remained high at 118.9 in 2024. The traditional winter peak in KD incidence disappeared after 2020. Instead, peak incidence was observed in the summer from 2021 to 2022 and in the spring from 2023 to 2024. The number of patients with respiratory syncytial virus infection, which had been highest during the fall and winter from 2015 to 2019, reached the highest levels during the spring and summer from 2021 onward. Conclusions: KD seasonality in Shiga Prefecture did not revert to the traditional winter-dominant pattern after COVID-19 infection mitigation measures were lifted. Continued surveillance is warranted to determine whether the winter-dominant pattern re-emerges.
- 25 March 2026
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 45 (10) , 872-878
Change in Seasonality of Kawasaki Disease After the COVID-19 Pandemic: A 10-year Survey in Shiga, Japan (2015–2024)
Background: During the coronavirus disease 2019 (COVID-19) pandemic, the seasonality of Kawasaki disease (KD) in Japan shifted from winter dominance to summer dominance. However, it remains unclear whether this pattern reverted after infection mitigation measures were lifted in 2023. Methods: We conducted a population-based retrospective survey among all hospitalized patients with KD in Shiga Prefecture, Japan, from 2015 to 2024. Monthly variations in the KD incidence from 2021 to 2024 were analyzed using the 2015–2019 period as reference. We also examined the seasonality of 10 common pediatric infectious diseases and seasonal influenza during the study period. Results: A total of 2077 patients with KD were identified. The KD incidence remained low during the implementation of public health measures against COVID-19 from 2020 to 2022. Subsequently, the incidence reached the maximum in 2023 (128.2 per 100,000 person-years), coinciding with the lifting of infection mitigation measures; the incidence remained high at 118.9 in 2024. The traditional winter peak in KD incidence disappeared after 2020. Instead, peak incidence was observed in the summer from 2021 to 2022 and in the spring from 2023 to 2024. The number of patients with respiratory syncytial virus infection, which had been highest during the fall and winter from 2015 to 2019, reached the highest levels during the spring and summer from 2021 onward. Conclusions: KD seasonality in Shiga Prefecture did not revert to the traditional winter-dominant pattern after COVID-19 infection mitigation measures were lifted. Continued surveillance is warranted to determine whether the winter-dominant pattern re-emerges.
- 12 October 2025
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
- Vol. 32 (12) , 938-944
A Pilot Study on the Efficacy and Safety of Sedation With Remimazolam in Japanese Patients Undergoing Endoscopic Retrograde Cholangiopancreatography
Objectives: Remimazolam is a novel, ultra‐short‐acting benzodiazepine. Remimazolam is characterized by rapid induction and recovery and low cardiopulmonary effects. The present study aimed to examine the safety and efficacy of a sedation method combining remimazolam and pentazocine during endoscopic retrograde cholangiopancreatography (ERCP) in a Japanese cohort. Methods: The present investigation was a single‐center, single‐arm, Phase 2 study. The primary endpoint was successful endoscopic sedation. The initial dose was induced with remimazolam (0.1 mg/kg) and pentazocine (3.75 mg). Remimazolam (0.05 mg/kg) and the same dose of pentazocine as the initial dose were added as needed in response to body movements or signs of discomfort during the procedure. Results: A total of 59 patients [median age (range): 75 years (48–87 years), 47 male (79.7%)] were enrolled. Successful endoscopic sedation was achieved in all patients. One patient (1.7%) experienced transient circulatory depression, with no instances of respiratory depression or need for flumazenil reversal. Post‐procedure alertness was achieved within 5 and 10 min in 52 (88.1%) and 58 patients (98.3%), respectively. Conclusion: Sedation with remimazolam and pentazocine in ERCP demonstrated high efficacy and a favorable safety profile in the Japanese population. Trial Registration: This trial was registered in the Japan Registry of Clinical Trials (jRCTs051230088)
- 12 October 2025
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
- Vol. 32 (12) , 938-944
A Pilot Study on the Efficacy and Safety of Sedation With Remimazolam in Japanese Patients Undergoing Endoscopic Retrograde Cholangiopancreatography
Objectives: Remimazolam is a novel, ultra‐short‐acting benzodiazepine. Remimazolam is characterized by rapid induction and recovery and low cardiopulmonary effects. The present study aimed to examine the safety and efficacy of a sedation method combining remimazolam and pentazocine during endoscopic retrograde cholangiopancreatography (ERCP) in a Japanese cohort. Methods: The present investigation was a single‐center, single‐arm, Phase 2 study. The primary endpoint was successful endoscopic sedation. The initial dose was induced with remimazolam (0.1 mg/kg) and pentazocine (3.75 mg). Remimazolam (0.05 mg/kg) and the same dose of pentazocine as the initial dose were added as needed in response to body movements or signs of discomfort during the procedure. Results: A total of 59 patients [median age (range): 75 years (48–87 years), 47 male (79.7%)] were enrolled. Successful endoscopic sedation was achieved in all patients. One patient (1.7%) experienced transient circulatory depression, with no instances of respiratory depression or need for flumazenil reversal. Post‐procedure alertness was achieved within 5 and 10 min in 52 (88.1%) and 58 patients (98.3%), respectively. Conclusion: Sedation with remimazolam and pentazocine in ERCP demonstrated high efficacy and a favorable safety profile in the Japanese population. Trial Registration: This trial was registered in the Japan Registry of Clinical Trials (jRCTs051230088)
- 31 July 2025
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 35 (7) , 1394-1399
Sustained reduction in Kawasaki disease during the post-acute phase of the coronavirus disease 2019 pandemic: a follow-up study in Shiga, Japan
Objective: To determine the epidemiologic change in Kawasaki disease during the post-acute phase of the coronavirus disease 2019 pandemic compared with the pre- and acute phases.Study design: A follow-up epidemiological study was conducted using data obtained from hospitalised patients with Kawasaki disease in Shiga Prefecture, Japan. The study period was divided into three phases: pre-pandemic (January 2015 to March 2020), acute pandemic (April 2020 to December 2020), and post-acute pandemic (January 2021 to December 2022). The incidence of Kawasaki disease was compared among these phases, focusing on monthly variation, patient age, and regional population density.Results: A total of 1,598 patients with Kawasaki disease were analysed. The per cent change in Kawasaki disease incidence from the pre-pandemic phase was −33.8% and −27.9% in the acute and post-acute phases, respectively. Monthly variation during the post-acute phase dramatically differed from that observed in the pre- and acute phases, with the highest incidence in August and the lowest in April. The Kawasaki disease reduction was larger in patients ≥4 years old during the post-acute phase. An association between population density and reduction in Kawasaki disease incidence was no longer observed during the post-acute phase, contrary to the result during the acute phase.Conclusions: The reduction in Kawasaki disease incidence in Shiga Prefecture remained in the post-acute phase of the coronavirus disease 2019 pandemic, although seasonal variation dramatically differed from the traditional pattern. Infection prevention measures by individuals might reduce Kawasaki disease development in the children ≥4 years old.
- 31 July 2025
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 35 (7) , 1394-1399
Sustained reduction in Kawasaki disease during the post-acute phase of the coronavirus disease 2019 pandemic: a follow-up study in Shiga, Japan
Objective: To determine the epidemiologic change in Kawasaki disease during the post-acute phase of the coronavirus disease 2019 pandemic compared with the pre- and acute phases.Study design: A follow-up epidemiological study was conducted using data obtained from hospitalised patients with Kawasaki disease in Shiga Prefecture, Japan. The study period was divided into three phases: pre-pandemic (January 2015 to March 2020), acute pandemic (April 2020 to December 2020), and post-acute pandemic (January 2021 to December 2022). The incidence of Kawasaki disease was compared among these phases, focusing on monthly variation, patient age, and regional population density.Results: A total of 1,598 patients with Kawasaki disease were analysed. The per cent change in Kawasaki disease incidence from the pre-pandemic phase was −33.8% and −27.9% in the acute and post-acute phases, respectively. Monthly variation during the post-acute phase dramatically differed from that observed in the pre- and acute phases, with the highest incidence in August and the lowest in April. The Kawasaki disease reduction was larger in patients ≥4 years old during the post-acute phase. An association between population density and reduction in Kawasaki disease incidence was no longer observed during the post-acute phase, contrary to the result during the acute phase.Conclusions: The reduction in Kawasaki disease incidence in Shiga Prefecture remained in the post-acute phase of the coronavirus disease 2019 pandemic, although seasonal variation dramatically differed from the traditional pattern. Infection prevention measures by individuals might reduce Kawasaki disease development in the children ≥4 years old.
- 26 May 2025
- Published by Wiley in Journal of Anatomy
- Vol. 247 (5) , 1091-1102
Change in diameters of the small intestine according to embryonic and early fetal growth
No previous studies have examined the diameter of the small intestine successively from the oral to the anal side of the small intestine. Therefore, the objectives of this study were to determine the successive intestinal diameters from the oral to the anal side (proximal to the distal) of the intestine, evaluate changes in diameter associated with growth, examine the effects of positional variation along the intestinal tract, investigate dynamic positional change from the extraembryonic coelom to the abdominal cavity, and assess the impact of complex tertiary intestinal loop formation. To this end, 14 human embryonic and fetal specimens with crown‐rump lengths (CRLs) ranging from 25.6 to 69.0 mm were selected for high‐resolution magnetic resonance imaging acquisition. The small intestines of the specimens were located in the extraembryonic coelom (herniation phase), transitioning phase, or abdominal cavity (return phase). The small intestine and mesentery were reconstructed in three dimensions, and the resulting morphological changes were observed and analyzed. Successive intestinal diameters from the oral to anal side of the small intestine were determined. Specifically, we observed the following: (1) gradual changes in the diameter of the position from the oral to the anal side in the jejunum–ileum, (2) the difference between the duodenum and jejunum–ileum, and (3) the difference between the superior part of the duodenum derived from the foregut and the remaining parts derived from the midgut. (4) Notably, the dynamic positional change from the extraembryonic coelom to the abdominal cavity, along with the rapid elongation and complex intestinal loop formation—a conspicuous phenomenon in the embryonic and early fetal periods—had little effect on the changes in diameter. This study indicates that increased diameter may serve as a useful indicator of intestinal development and differentiation, independent of tertiary intestinal loop formation and positional changes into and out of the abdominal cavity.
- 26 May 2025
- Published by Wiley in Journal of Anatomy
- Vol. 247 (5) , 1091-1102
Change in diameters of the small intestine according to embryonic and early fetal growth
No previous studies have examined the diameter of the small intestine successively from the oral to the anal side of the small intestine. Therefore, the objectives of this study were to determine the successive intestinal diameters from the oral to the anal side (proximal to the distal) of the intestine, evaluate changes in diameter associated with growth, examine the effects of positional variation along the intestinal tract, investigate dynamic positional change from the extraembryonic coelom to the abdominal cavity, and assess the impact of complex tertiary intestinal loop formation. To this end, 14 human embryonic and fetal specimens with crown‐rump lengths (CRLs) ranging from 25.6 to 69.0 mm were selected for high‐resolution magnetic resonance imaging acquisition. The small intestines of the specimens were located in the extraembryonic coelom (herniation phase), transitioning phase, or abdominal cavity (return phase). The small intestine and mesentery were reconstructed in three dimensions, and the resulting morphological changes were observed and analyzed. Successive intestinal diameters from the oral to anal side of the small intestine were determined. Specifically, we observed the following: (1) gradual changes in the diameter of the position from the oral to the anal side in the jejunum–ileum, (2) the difference between the duodenum and jejunum–ileum, and (3) the difference between the superior part of the duodenum derived from the foregut and the remaining parts derived from the midgut. (4) Notably, the dynamic positional change from the extraembryonic coelom to the abdominal cavity, along with the rapid elongation and complex intestinal loop formation—a conspicuous phenomenon in the embryonic and early fetal periods—had little effect on the changes in diameter. This study indicates that increased diameter may serve as a useful indicator of intestinal development and differentiation, independent of tertiary intestinal loop formation and positional changes into and out of the abdominal cavity.
- 12 February 2025
- Published by Wiley in The Anatomical Record
- Vol. 308 (12) , 3142-3156
Primary sulci formation in human cerebral cortex development
We aimed to determine the timing of appearance and the morphologic and morphometric features of the initial human cerebral sulcal formation. Using high‐resolution magnetic resonance images obtained from 33 samples between 11 and 16 weeks (w) of gestation (crown‐rump length <130 mm), the cerebral surface and internal structures on serial two‐dimensional planes and all possible sulci on three‐dimensional reconstructions were marked, allowing comparison of the positions of the sulci in the samples and inter‐samples. Our method provided accurate conclusions regarding the timing of sulcal formation. Detection timing was as early as and earlier than those in previous studies using anatomical dissection and magnetic resonance imaging (MRI), respectively: <12 w for the callosum, <13 w for the hippocampal, calcarine, and parieto‐occipital sulci, and < 15 w for the lateral sulcus. Occasionally, an olfactory sulcus was detected. However, the cingulate sulcus could not be definitely identified. The lateral sulcus gradually appeared and changed shape. The lengths of the left and right sides of the olfactory sulci and the left side of the hippocampal sulcus increased linearly with the CRL. The length of the right side of the hippocampal sulcus and the left and right sides of the calcarine, parieto‐occipital, and not determined_a sulci did not increase with the CRL The depth of the all sulci, except for the parieto‐occipital sulci, increased linearly with the CRL. The sulci might not arise as if they elongate gradually but arise simultaneously over some distance. We determined the timing of the initial sulcal formation using high‐resolution MRI. Our findings may significantly impact prenatal diagnosis and research on neurodevelopmental disorders.
- 12 February 2025
- Published by Wiley in The Anatomical Record
- Vol. 308 (12) , 3142-3156
Primary sulci formation in human cerebral cortex development
We aimed to determine the timing of appearance and the morphologic and morphometric features of the initial human cerebral sulcal formation. Using high‐resolution magnetic resonance images obtained from 33 samples between 11 and 16 weeks (w) of gestation (crown‐rump length <130 mm), the cerebral surface and internal structures on serial two‐dimensional planes and all possible sulci on three‐dimensional reconstructions were marked, allowing comparison of the positions of the sulci in the samples and inter‐samples. Our method provided accurate conclusions regarding the timing of sulcal formation. Detection timing was as early as and earlier than those in previous studies using anatomical dissection and magnetic resonance imaging (MRI), respectively: <12 w for the callosum, <13 w for the hippocampal, calcarine, and parieto‐occipital sulci, and < 15 w for the lateral sulcus. Occasionally, an olfactory sulcus was detected. However, the cingulate sulcus could not be definitely identified. The lateral sulcus gradually appeared and changed shape. The lengths of the left and right sides of the olfactory sulci and the left side of the hippocampal sulcus increased linearly with the CRL. The length of the right side of the hippocampal sulcus and the left and right sides of the calcarine, parieto‐occipital, and not determined_a sulci did not increase with the CRL The depth of the all sulci, except for the parieto‐occipital sulci, increased linearly with the CRL. The sulci might not arise as if they elongate gradually but arise simultaneously over some distance. We determined the timing of the initial sulcal formation using high‐resolution MRI. Our findings may significantly impact prenatal diagnosis and research on neurodevelopmental disorders.